Newsroom

Seven years ago, Glen Miller was diagnosed with stage 4 colorectal cancer with liver metastases. His doctors gave him a year to live and recommended palliative chemotherapy, but Glen sought a second opinion. Doctors at the University of Colorado Medical Center felt his cancer could be operated on but would need to be reduced with chemotherapy. After multiple rounds of chemo and several surgeries, the cancer in his liver kept returning. Doctors then implanted a Hepatic Artery Infusion (HAI) pump to deliver medicine directly to his liver. Since receiving HAI therapy, Glen has shown no evidence of disease for nearly three years and credits seeking a second opinion for being here today. University of Colorado Cancer Center

Surgical oncologist Leonid Cherkassky, MD, and medical oncologist Anuradha Krishnamurthy, MBBS, discuss the use of Hepatic Artery Infusion (HAI) therapy and emphasize the importance of providing patients with information on all available treatment options. Roswell Park Comprehensive Cancer Center

UPMC surgical oncologist Dr. James Fingpank describes the use of Hepatic Artery Infusion (HAI), including what it is, how it works, surgical implantation of the HAI pump and subsequent administration of HAI therapy with the pump. UPMC Health Beat

Grady Hebert thought he had beat colon cancer, but when it returned and spread to his liver, his doctors told him it was inoperable. Not willing to give up, he sought out help from Dr. Sepideh Gholami at Northwell Health’s new Hepatic Artery Infusion (HAI) pump program in New York. He received HAI therapy and underwent successful surgery to remove the tumors from his liver. Northwell Health

Mayo Clinic surgical oncologist Dr. Cornelius Thiels discusses the use of HAI therapy in treating liver metastases in people with colorectal cancer. The Mayo Clinic

While surgery was recommended for removing the tumors that had metastasized from Cheryl Andersen’s colon to her liver, they were initially too large to remove. However, treatment with Hepatic Artery Infusion (HAI) therapy under the care of Northwell Health’s Dr. Sepideh Golami shrunk the tumors, enabling her surgeon to successfully remove them all. A year after receiving her HAI pump, an MRI a scan showed that Cheryl was cancer free. Northwell Health

Jashodeep Datta, MD, of the University of Miami and Sylvester Comprehensive Cancer Center, discusses the use of Hepatic Artery Infusion (HAI) therapy, his thoughts on how it compares to bilobar Y90 in patients with unresectable multifocal bilobar disease, and why he believes the use of HAI therapy will continue to become more mainstream with expanded applications and accessibility. IO Learning

Data from a single-arm Phase 2 study presented at the 2024 ASCO Gastrointestinal Cancers Symposium found that patients with advanced intrahepatic cholangiocarcinoma (iCCA) who were treated with Hepatic Artery Infusion (HAI) therapy combined with systemic chemotherapy showed improved overall survival (OS) rates compared to previous trials in patients treated with systemic chemotherapy alone. DocWire News

Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, has joined a select number of institutions nationwide that offer Hepatic Artery Infusion (HAI) therapy for patients with liver tumors. Newswise

Researchers from several top academic medical institutions will present their independent research findings related to HAI therapy in live presentations, oral abstracts, and posters at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20, 2024 in San Francisco, California. An increasing body of clinical evidence and modernized therapy protocols have driven wider adoption of HAI therapy as more physicians and patients have learned about the benefits of the treatment. CISON - PR Web

Dr. Francisco Macedo, a surgical oncologist at HCA Florida North Florida Hospital, explains how the use of Hepatic Artery Infusion (HAI) therapy can be used to help treat liver metastases in people with colorectal cancer WCJB-TV

The Mays Cancer Center, home to the UT Health San Antonio MD Anderson Cancer Center, has launched Hepatic Artery Infusion (HAI) therapy for colorectal patients whose tumors are inoperable and have spread the liver. This National Cancer Institute (NCI)-designated Cancer Center is currently only one of two facilities in Texas offering HAI therapy. Offering Hepatic Artery Infusion therapy locally gives patients from San Antonio and throughout South Texas an opportunity to receive care close to home. The University of Texas Health Science Center at San Antonio

Colorectal cancer ranks fourth in causing cancer-related deaths in the U.S. For up to 25% of patients diagnosed with this disease, the cancer metastasizes to the liver, where it becomes challenging to treat. Now, an innovative chemotherapy delivery system can help colorectal cancer patients with inoperable liver tumors due to metastasis. This breakthrough treatment minimizes toxic exposure and makes surgical interventions feasible for some patients with colon cancer metastasized to the liver. Hospmedica

Jersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care. Hackensack Meridian Health

Physicians at Cedars-Sinai Cancer are using a unique chemotherapy delivery system that offers hope to colorectal cancer patients whose disease has spread and who now have inoperable liver tumors. Cedars-Sinai is one of the few centers in the area to offer the therapy, called Hepatic Artery Infusion (HAI). Cedars Sinai

A multidisciplinary approach is ideal in training nurses to use Hepatic Artery Infusion pumps (HAIP) for chemotherapy delivery, according to Kathleen Gander DNP, APRN, CNS. Oncology Nursing News

UCSF’s Division of Surgical Oncology is currently the only center in Northern California area offering surgical insertion of Hepatic Artery Infusion (HAI) pumps for patients. UCSF

Intera Oncology® Inc., manufacturer of the only FDA-approved pump for Hepatic Artery Infusion (HAI) therapy for the treatment of intrahepatic cholangiocarcinoma (bile duct cancer confined to the liver) and colorectal cancer liver metastases, will showcase its Intera 3000 HAI Pump as a sponsor of the 10th annual Cholangiocarcinoma Foundation Conference April 12 to 15 in Salt Lake City, Utah.

Intera Oncology® Inc. has reintroduced Hepatic Artery Infusion (HAI) therapy to the market after its discontinuation in 2018 by the prior manufacturer dismayed patients and physicians.

Intera Oncology® Inc., the manufacturer of the only FDA-approved implantable pump used for Hepatic Artery Infusion (HAI) therapy, will showcase its Intera 3000 HAI Pump at the 2023 ASCO Gastrointestinal Cancer Symposium, taking place at the Moscone West in San Francisco, Calif. from January 19 to 20, 2023.

In June, AdventHealth Cancer Institute (AHCI) became the second center in Florida to offer Hepatic Artery Infusion (HAI) therapy as a treatment option for patients with colorectal liver metastases or cholangiocarcinoma (bile duct cancer). AHCI spent nearly a year planning and preparing to provide HAI therapy in the Central Florida community, including training and support for medical oncology, surgical oncology nuclear medicine, infusion unit nurses, and others to ensure the best patient outcomes. Florida Medical Association

A new study supports a delivery system used in the 90s to target some of the hardest to treat cancers without impacting the rest of the body. WINK News

OHSU surgeon’s innovative approach targets deadly cholangiocarcinoma of the liver. Oregon Health & Sciences University

Physicians with UAB Medicine, O'Neal Comprehensive Cancer Center, and the University of Alabama at Birmingham Heersink School of Medicine have launched a new Hepatic Artery Infusion Pump Program — the only program of its type in Alabama — to offer more treatment options to patients with colon or rectal cancer that has spread to the liver. University of Alabama at Birmingham

One of the first patients in the region to undergo a targeted cancer therapy directed at the liver through a pump implanted under the skin has been declared cancer-free. UCDavis

Intera Oncology is proud to announce that the FDA has approved the manufacture of the Intera 3000 Hepatic Artery Infusion (HAI) Pump for HAI therapy for patients with colorectal cancer and cholangiocarcinoma. The Intera 3000HAI Pump is now the only FDA-approved pump for HAI. “We formed Intera Oncology to bring this pump back to market after it was discontinued by another company. We could not let those who stood to benefit from HAI therapy go without that option,” said Michael Gaisford, president and CEO of Intera Oncology. “We are thrilled that we have accomplished our mission and that HAI therapy will be available to those who need it.”

A chemotherapy infusion pump is giving more time to people whose metastatic colorectal cancer has spread to the liver and who may have been told they are out of options. Duke Health surgical oncologists were the first to implant the Hepatic Artery Infusion (HAI) pump after it received FDA approval. Duke Health

Michael Gaisford has been named CEO of Intera Oncology, a medical device company dedicated to ensure Hepatic Artery Infusion therapy is available to any patient who could benefit from it. Gaisford brings 15 years’ experience leading strategy, marketing, and product management teams. Prior to Intera, Gaisford was Director of Marketing for Stratasys Healthcare Solutions where he oversaw global marketing programs across medical and dental markets. At Boston Scientific, he held positions in corporate strategy, marketing and divisional product marketing. Gaisford previously worked at Genentech, CVS/Pharmacy, and McKinsey & Company. He holds an MBA from the Tuck School of Business at Dartmouth and BS from Stanford University.

Two doctors determined to resurrect a medical pump that increases survival of some patients with colorectal cancer and cholangiocarcinoma have launched Intera Oncology. Drs. Jonathan Reis and David Dove both have loved ones who benefitted from the only FDA-approved pump that delivers chemotherapy directly to the liver via “Hepatic Artery Infusion therapy” (HAI). When they found that the pump was to be discontinued, the doctors formed Intera Oncology to once again make the pump available to those who may benefit from it.